AKT1 and triple-negative breast carcinoma: In BRCA-proficient triple negative breast cancer cells, treatment with olaparib did not show significant regulation in the expression and phosphorylation of AKT, but targeting of PI3K activity by BKM120 synergistically increased sensitivity to olaparib in inhibition of cell proliferation55.